Merck, Inc.
🇵🇭Philippines
A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00863590
Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)
Completed
- Conditions
- Hepatitis C, ChronicHCV-1Genotype 1
- Interventions
- Biological: Peginterferon alfa-2b (PEG)Drug: Ribavirin (RBV)
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 133
- Registration Number
- NCT00863109
A Comparison of Measurements of Ketone Body Flux Versus Ketone Body Concentration as a Pharmacodynamic Marker of Hepatic Fatty Acid Oxidation (0000-110)
Phase 1
Completed
- Conditions
- Diabetes
- Interventions
- Drug: Stable isotope tracer (13-C(4)-BHB)
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2017-11-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00860392
Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)
Phase 1
Terminated
- Conditions
- Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia (ALL)Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia (CML)
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2015-09-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 9
- Registration Number
- NCT00860535
Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 9
- Registration Number
- NCT00858234
MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)
Phase 1
Completed
- Conditions
- Hepatitis C
- Interventions
- Biological: MRKAd5 HIV-1 gag vaccine (V520)
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 17
- Registration Number
- NCT00857311
The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127)
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT00856960
ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)
Terminated
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: Peginterferon alfa-2bDrug: Ribavirin
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 902
- Registration Number
- NCT00856024
An Observational Study of Fungal Biomarkers (MK-0000-089)
Completed
- Conditions
- Aspergillosis
- Interventions
- Other: No Intervention
- First Posted Date
- 2009-03-03
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 116
- Registration Number
- NCT00854607
Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)
Phase 1
Completed
- Conditions
- Cervical CancerVaginal CancerVulvar CancerGenital WartsHuman Papilloma Virus
- Interventions
- Biological: Octavalent HPV with 15 mcg IMX / AAHSBiological: Octavalent HPV with 30 mcg IMX / AAHSBiological: Octavalent HPV with 60 mcg IMX / AAHSBiological: Octavalent HPV with 120 mcg IMX / AAHS
- First Posted Date
- 2009-02-26
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 158
- Registration Number
- NCT00851643
© Copyright 2025. All Rights Reserved by MedPath